(HPTX) (HPTX) Stock Price, News & Analysis

Company Overview

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company's products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company's products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 786,899 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HPTX Stock Analysis - Frequently Asked Questions

How were (HPTX)'s earnings last quarter?

(HPTX) (NASDAQ:HPTX) released its quarterly earnings data on Thursday, February, 26th. The biopharmaceutical company reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.67. The firm's revenue for the quarter was up 65.6% on a year-over-year basis.

What other stocks do shareholders of (HPTX) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (HPTX) investors own include Tivity Health (TVTY), Bausch Health Cos (BHC), Berkshire Hills Bancorp (BHLB), Cognex (CGNX), Cigna Group (CI), Cynosure (CYNO) and Depomed (DEPO).

Company Calendar

• Last Earnings: 2/26/2015
• Today: 6/29/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HPTX
• CIK: 1386858
• Web: N/A
• Phone: +1-650-7457802
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A